Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Basit Öğe Kaydı
dc.contributor.authorTonyali, Onder
dc.contributor.authorCoskun, Ugur
dc.contributor.authorYuksel, Sinemis
dc.contributor.authorInanc, Mevlude
dc.contributor.authorBal, Oznur
dc.contributor.authorAkman, Tulay
dc.contributor.authorYazilitas, Dogan
dc.date.accessioned2024-04-24T16:10:57Z
dc.date.available2024-04-24T16:10:57Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. Methods: Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. Results: Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. Conclusions: In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.breast.2015.11.006
dc.identifier.endpage26en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.pmid26801412
dc.identifier.scopus2-s2.0-84959084796
dc.identifier.scopusqualityQ1
dc.identifier.startpage22en_US
dc.identifier.urihttps://doi.org/10.1016/j.breast.2015.11.006
dc.identifier.urihttps://hdl.handle.net/11468/15203
dc.identifier.volume25en_US
dc.identifier.wosWOS:000368373500003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreast
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectAdjuvant Therapyen_US
dc.subjectTrastuzumaben_US
dc.subjectBrain Metastasisen_US
dc.titleRisk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumaben_US
dc.titleRisk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu